Comparative Pharmacology
Head-to-head clinical analysis: DILTIAZEM HYDROCHLORIDE IN 0 72 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILTIAZEM HYDROCHLORIDE IN 0 72 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
3-4.5 hours; prolonged in hepatic impairment (up to 10 hours) and in elderly
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: 2-4% unchanged; hepatic metabolism with biliary excretion; fecal elimination accounts for ~10%
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte